By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EyeGate Pharma 

100 Beaver Street

Waltham  Massachusetts  02453-8425  U.S.A.
Phone: 781-788-8869 Fax:


Medical Device

Company News
EyeGate Pharma To Present At The 17th Rodman & Renshaw 2015 Annual Global Investment Conference 9/1/2015 12:35:28 PM
EyeGate Pharma Announces Closing Of Public Offering Of Common Stock And Warrants 8/5/2015 1:25:31 PM
EyeGate Pharma Announces Pricing Of $10,000,000 Public Offering Of Common Stock And Warrants 7/31/2015 7:09:38 AM
EyeGate Pharma Receives USPTO Notice Of Allowance For Proprietary Dexamethasone Phosphate Formulation 7/24/2015 7:17:18 AM
EyeGate Pharma Treats First Patient In Phase Ib / 2a Trial Of EGP-437 In Macular Edema 7/14/2015 7:17:29 AM
EyeGate Pharma Signs Licensing Agreement With Valeant (VRX) For EGP-437 Combination Product In Uveitis 7/10/2015 6:59:38 AM
EyeGate Pharma Receives Positive Guidance From FDA On NDA Filing Requirements Of EGP-437 For The Treatment Of Anterior Uveitis 5/4/2015 7:32:28 AM
EyeGate Pharma Names Michael B. Raizman, MD, Consulting Chief Medical Officer 3/2/2015 7:56:25 AM
EyeGate Pharma Announces Closing Of Initial Public Offering Of Approximately $4,100,000 Of Common Stock 2/20/2015 7:14:24 AM
EyeGate Pharma Prices $4,100,000 Initial Public Offering 2/13/2015 7:45:48 AM